The standardized uptake value for F‐18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival

The objective of this study was to evaluate cervical tumor uptake of F‐18 fluorodeoxyglucose (FDG) measured as the maximal standardized uptake value (SUVmax) by positron emission tomography (PET) and its association with treatment response and prognosis in patients with cervical cancer.

[1]  金子 文成,et al.  長時間歩行時の下肢筋の活動状態:[ 18 F]fluorodeoxyglucoseを用いたPositron Emission Tomographyによる検討 , 2008 .

[2]  P. Grigsby,et al.  FDG-PET imaging for the assessment of physiologic volume response during radiotherapy in cervix cancer. , 2006, International journal of radiation oncology, biology, physics.

[3]  P. Grigsby,et al.  F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. , 2006, Gynecologic oncology.

[4]  R. Welsh,et al.  Positron-emission tomography as a prognostic tool for early-stage lung cancer. , 2006, American journal of surgery.

[5]  R. Govindan,et al.  Prognostic Value of Fluorodeoxyglucose Positron Emission Tomography in Non-small Cell Lung Cancer: A Review , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  H. Dittmann,et al.  Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? , 2006, European journal of nuclear medicine and molecular imaging.

[7]  H. Dittmann,et al.  Is standardised 18F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  P. Grigsby,et al.  Preoperative lymph node staging of early‐stage cervical carcinoma by [18F]‐fluoro‐2‐deoxy‐D‐glucose–positron emission tomography , 2005, Cancer.

[9]  Joos V Lebesque,et al.  Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. , 2005, European journal of cancer.

[10]  T. Bilfinger,et al.  Increased standardized uptake value in the primary lesion predicts nodal or distant metastases at presentation in lung cancer. , 2005, Clinical lung cancer.

[11]  K. Forster,et al.  [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Leblanc,et al.  FDG-PET prediction of head and neck squamous cell cancer outcomes. , 2004, Archives of otolaryngology--head & neck surgery.

[13]  S. Larson,et al.  Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Mohamed Allaoua,et al.  Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. , 2004, International journal of radiation oncology, biology, physics.

[15]  Imran Zoberi,et al.  Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Coleman,et al.  Positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer , 2004 .

[17]  T. Yen,et al.  18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  R. Coleman,et al.  Positron emission tomography with 2-deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[19]  Farrokh Dehdashti,et al.  Improved prognostic value of 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  M. Tian,et al.  Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  M. Nadji,et al.  Expression of glucose transporter-1 in cervical cancer and its precursors. , 2002, Gynecologic oncology.

[22]  P. Grigsby,et al.  Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. , 2002, International journal of radiation oncology, biology, physics.

[23]  R. Wahl,et al.  Expression of hexokinase II and Glut-1 in untreated human breast cancer. , 2002, Nuclear medicine and biology.

[24]  F Dehdashti,et al.  Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Airley,et al.  Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  M. Schwaiger,et al.  Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  Barry A. Siegel,et al.  FDG-PET Evaluation of Carcinoma of the Cervix. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[28]  L. Adler,et al.  Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  B. Meunier,et al.  Prognostic factors of the uterine cervix adenocarcinoma. , 1998, European journal of obstetrics, gynecology, and reproductive biology.

[30]  P. Grigsby,et al.  Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix. , 1998, International journal of radiation oncology, biology, physics.

[31]  S. Chow,et al.  Prognostic factors of primary adenocarcinoma of the uterine cervix. , 1998, Gynecologic oncology.

[32]  A. Brahme,et al.  Principles and Practice of Radiation Oncology , 1992 .

[33]  J. Hong,et al.  Prognostic assessment of tumor regression after external irradiation for cervical cancer. , 1992, International journal of radiation oncology, biology, physics.

[34]  P. Disaia,et al.  A prospective surgical pathological study of stage I squamous carcinoma of the cervix: a Gynecologic Oncology Group Study. , 1989, Gynecologic oncology.

[35]  J. van Nagell,et al.  Radiation‐induced tumor regression as a prognostic factor in patients with invasive cervical cancer , 1982, Cancer.

[36]  E S Hafez,et al.  Uterine cervix. , 1969, Science.

[37]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[38]  D.,et al.  Regression Models and Life-Tables , 2022 .